Spotlight Innovation Inc.
http://www.spotlightinnovation.com
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Spotlight Innovation Inc.
Asia Deal Watch: Avenue Takes On AnnJi’s Spinal And Bulbar Muscular Atrophy Candidate
Plus deals involving Ono/PeptiDream, Onconic/Livzon, Teijin/Novartis, Eisai/Biogen, Abbisko/Allist, Daewoong/M8, GC Biopharma/Catalyst and KYM Biosciences/AstraZeneca.
Shionogi Reveals Strategy For COVID-19 Drug Xocova
Shionogi is hoping to demonstrate the efficacy of its oral COVID-19 candidate Xocova through an appropriate primary endpoint in its Phase III trial, while the Japanese firm is also eyeing global expansion for the drug should a world-first domestic approval be granted.
Deal Watch: Cidara Licenses US Rights To Antifungal Under FDA Review To Melinta
Cidara gets $30m up front for US rights to the weekly echinocandin candidate for candidemia and invasive candidiasis. Takeda walks away from oncolytic virus candidate licensed from Turnstone.
Tech Transfer Roundup: Repeat Business As Boehringer, Vanderbilt Collaborate Further On KRAS
This month's roundup also records a second tie-up between Florida State and Spotlight Innovations, while Taiwan's Lin Biosciences licenses global rights to a CDC7 kinase inhibitor from Columbia and Memorial Sloan Kettering.
Company Information
- Industry
- Pharmaceuticals
-
Pharmaceuticals
- Specialty Pharmaceuticals
- Vaccines
- Other Names / Subsidiaries
-
- Celtic Biotech Iowa Inc.
- Memcine Pharmaceuticals Inc.
- American Exploration Corporation
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice